• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服亚胺甲氧基氨噻唑基头孢菌素R-3746的体外活性

In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.

作者信息

Chin N X, Neu H C

机构信息

Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032.

出版信息

Antimicrob Agents Chemother. 1988 May;32(5):671-7. doi: 10.1128/AAC.32.5.671.

DOI:10.1128/AAC.32.5.671
PMID:3260766
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC172250/
Abstract

The in vitro activity of R-3746, an iminomethoxy aminothiazolyl cephalosporin with a CH2OCH3 moiety at position 3, was compared with those of other antibiotics. R-3746 inhibited the majority of hemolytic streptococci (groups A, B, C, F, and G) and Streptococcus pneumoniae at less than 0.06 micrograms/ml, which was comparable to the activity of amoxicillin, 2- to 8-fold more active than cefixime, and 16- to 64-fold more active than cefaclor and cephalexin. Ninety percent of beta-lactamase-producing Haemophilus influenzae and Neisseria gonorrhoeae were inhibited at a concentration 0.25 micrograms/ml, but it was less active against Branhamella spp. It did not inhibit (MIC, greater than 16 micrograms/ml) enterococci, viridans group streptococci, or methicillin-resistant staphylococci. The MICs of R-3746 for 90% of strains tested for Escherichia coli; Klebsiella pneumoniae; Citrobacter diversus; Proteus mirabilis; and Salmonella, Shigella, and Yersinia spp. were less than or equal to 1 micrograms/ml. It was two- to eightfold less active than cefixime but was markedly superior to cefaclor, cephalexin, amoxicillin-clavulanate, and trimethoprimsulfamethoxazole. R-3746 inhibited 50% of Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, Morganella spp., Providencia spp., Proteus vulgaris, and Serratia marcescens at less than or equal to 8 micrograms/ml. Pseudomonas spp. were resistant. Fifty percent of Clostridium spp. were inhibited by 0.5 micrograms/ml, but MICs for Bacteroides spp. were greater than 128 micrograms/ml. R-3746 was not appreciably hydrolyzed by most chromosomal and plasmid-mediated beta-lactamases.

摘要

将在3位带有CH2OCH3基团的亚氨基甲氧基氨基噻唑基头孢菌素R-3746的体外活性与其他抗生素进行了比较。R-3746对大多数溶血性链球菌(A、B、C、F和G组)和肺炎链球菌的抑制浓度低于0.06微克/毫升,这与阿莫西林的活性相当,比头孢克肟活性高2至8倍,比头孢克洛和头孢氨苄活性高16至64倍。90%产β-内酰胺酶的流感嗜血杆菌和淋病奈瑟菌在浓度为0.25微克/毫升时受到抑制,但对布兰汉菌属活性较低。它不抑制(最低抑菌浓度,大于16微克/毫升)肠球菌、草绿色链球菌或耐甲氧西林葡萄球菌。R-3746对90%受试的大肠杆菌、肺炎克雷伯菌、异型枸橼酸杆菌、奇异变形杆菌以及沙门菌属、志贺菌属和耶尔森菌属菌株的最低抑菌浓度小于或等于1微克/毫升。它比头孢克肟活性低2至8倍,但明显优于头孢克洛、头孢氨苄、阿莫西林-克拉维酸和甲氧苄啶-磺胺甲恶唑。R-3746在小于或等于8微克/毫升时抑制50%的阴沟肠杆菌、产气肠杆菌、弗氏枸橼酸杆菌、摩根菌属、普罗威登斯菌属、普通变形杆菌和粘质沙雷菌。铜绿假单胞菌属耐药。50%的梭菌属在0.5微克/毫升时受到抑制,但对拟杆菌属的最低抑菌浓度大于128微克/毫升。R-3746不会被大多数染色体介导和质粒介导的β-内酰胺酶明显水解。

相似文献

1
In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.口服亚胺甲氧基氨噻唑基头孢菌素R-3746的体外活性
Antimicrob Agents Chemother. 1988 May;32(5):671-7. doi: 10.1128/AAC.32.5.671.
2
Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.新型口服头孢菌素FK482的体外活性及β-内酰胺酶稳定性比较
Antimicrob Agents Chemother. 1989 Oct;33(10):1795-800. doi: 10.1128/AAC.33.10.1795.
3
In vitro activity and beta-lactamase stability of the new oral cephalosporin Bay v 3522.新型口服头孢菌素Bay v 3522的体外活性及β-内酰胺酶稳定性
Eur J Clin Microbiol Infect Dis. 1990 Sep;9(9):685-91. doi: 10.1007/BF01964273.
4
In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime.新型广谱、β-内酰胺酶稳定口服头孢菌素——头孢克肟的体外活性
Pediatr Infect Dis J. 1987 Oct;6(10):958-62. doi: 10.1097/00006454-198710000-00034.
5
Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.新型口服活性头孢菌素FR 17027的体外活性及β-内酰胺酶稳定性比较
Antimicrob Agents Chemother. 1984 Aug;26(2):174-80. doi: 10.1128/AAC.26.2.174.
6
Tigemonam, an oral monobactam.替吉莫南,一种口服单环β-内酰胺类抗生素。
Antimicrob Agents Chemother. 1988 Jan;32(1):84-91. doi: 10.1128/AAC.32.1.84.
7
Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.头孢泊肟:比较抗菌活性、生长条件的影响及杀菌活性。
Infection. 1991 Sep-Oct;19(5):370-6. doi: 10.1007/BF01645371.
8
Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218.研究性口服和肠胃外头孢菌素BK-218的抗菌活性
Eur J Clin Microbiol Infect Dis. 1992 Feb;11(2):181-8. doi: 10.1007/BF01967075.
9
Comparative in vitro activity and beta-lactamase stability of RU29246, the active metabolite of HR916B.HR916B的活性代谢产物RU29246的体外活性及β-内酰胺酶稳定性比较
Eur J Clin Microbiol Infect Dis. 1992 Jul;11(7):652-9. doi: 10.1007/BF01961678.
10
In vitro activity of a new cephalosporin ME-1206 compared with other agents.新型头孢菌素ME-1206与其他药物的体外活性比较。
Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):417-24. doi: 10.1016/0732-8893(91)90068-q.

引用本文的文献

1
Penetration of cefpodoxime into uterine and vaginal secretions from postpartum women after a single oral dose of cefpodoxime proxetil.单次口服头孢泊肟酯后头孢泊肟在产后妇女子宫和阴道分泌物中的渗透情况。
Antimicrob Agents Chemother. 1996 Aug;40(8):1832-4. doi: 10.1128/AAC.40.8.1832.
2
In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics.头孢泊肟与其他口服β-内酰胺类抗生素相比的体外活性。
Infection. 1994 Sep-Oct;22(5):370-5. doi: 10.1007/BF01715556.
3
beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance.β-内酰胺酶稳定性及口服头孢菌素对具有明确耐药机制菌株的体外活性。
Antimicrob Agents Chemother. 1989 Aug;33(8):1313-7. doi: 10.1128/AAC.33.8.1313.
4
Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.新型口服头孢菌素FK482的体外活性及β-内酰胺酶稳定性比较
Antimicrob Agents Chemother. 1989 Oct;33(10):1795-800. doi: 10.1128/AAC.33.10.1795.
5
In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.头孢泊肟酯(U-76,252;CS-807)对卡他布兰汉菌临床分离株的体外活性。
Antimicrob Agents Chemother. 1989 Jan;33(1):113-4. doi: 10.1128/AAC.33.1.113.
6
Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis.头孢泊肟酯在接受血液透析的终末期肾衰竭患者中的应用。
Infection. 1990 May-Jun;18(3):157-62. doi: 10.1007/BF01642104.
7
Cefpodoxime proxetil concentrations in head and neck tissues.头孢泊肟酯在头颈部组织中的浓度。
Infection. 1991 Jan-Feb;19(1):41-3. doi: 10.1007/BF01643757.
8
In vitro activity of cefpodoxime against staphylococci in comparison to other cephalosporins.头孢泊肟对葡萄球菌的体外活性与其他头孢菌素的比较。
Eur J Clin Microbiol Infect Dis. 1991 Jul;10(7):585-8. doi: 10.1007/BF01967279.
9
In vitro activity of cefpodoxime, a new oral cephalosporin, compared with that of nine other antimicrobial agents.新型口服头孢菌素头孢泊肟的体外活性与其他九种抗菌药物的比较。
Eur J Clin Microbiol Infect Dis. 1991 Jul;10(7):573-81. doi: 10.1007/BF01967277.
10
Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.头孢泊肟:比较抗菌活性、生长条件的影响及杀菌活性。
Infection. 1991 Sep-Oct;19(5):370-6. doi: 10.1007/BF01645371.

本文引用的文献

1
Method of reliable determination of minimal lethal antibiotic concentrations.可靠测定最低致死抗生素浓度的方法。
Antimicrob Agents Chemother. 1980 Nov;18(5):699-708. doi: 10.1128/AAC.18.5.699.
2
In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.新型口服活性头孢烯抗生素FK 027的体外和体内抗菌特性
Antimicrob Agents Chemother. 1984 Jan;25(1):98-104. doi: 10.1128/AAC.25.1.98.
3
Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.新型口服活性头孢菌素FR 17027的体外活性及β-内酰胺酶稳定性比较
Antimicrob Agents Chemother. 1984 Aug;26(2):174-80. doi: 10.1128/AAC.26.2.174.
4
The pharmacokinetic and bactericidal characteristics of oral cefixime.口服头孢克肟的药代动力学及杀菌特性
Clin Pharmacol Ther. 1985 Nov;38(5):590-4. doi: 10.1038/clpt.1985.229.
5
In vitro activities of Ro 19-5247 and Ro 15-8074, new oral cephalosporins.新型口服头孢菌素Ro 19 - 5247和Ro 15 - 8074的体外活性
Antimicrob Agents Chemother. 1986 Sep;30(3):429-34. doi: 10.1128/AAC.30.3.429.
6
In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).两种口服头孢菌素头孢替胺(Ro 19-5247)和头孢他美酯(Ro 15-8074)的体外活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1986 Sep;30(3):423-8. doi: 10.1128/AAC.30.3.423.
7
In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.新型口服头孢菌素CS-807的体外和体内抗菌活性
Antimicrob Agents Chemother. 1987 Jul;31(7):1085-92. doi: 10.1128/AAC.31.7.1085.